What made sesquiterpene lactones reach cancer clinical trials?

被引：530

作者：

Ghantous, Akram ^{[1
,2
]}

Gali-Muhtasib, Hala ^{[1
,2
]}

Vuorela, Heikki ^{[3
]}

Saliba, Najat A. ^{[2
,4
]}

Darwiche, Nadine ^{[1
,2
]}

机构：

[1] Amer Univ Beirut, Dept Biol, Beirut 11072020, Lebanon

[2] Amer Univ Beirut, Nat Conservat Ctr Sustainable Futures, Beirut 11072020, Lebanon

[3] Univ Helsinki, Fac Pharm, Div Pharmaceut Biol, FIN-00014 Helsinki, Finland

[4] Amer Univ Beirut, Dept Chem, Beirut 11072020, Lebanon

来源：

DRUG DISCOVERY TODAY | 2010年 / 15卷 / 15-16期

关键词：

NF-KAPPA-B; STRUCTURE-CYTOTOXICITY RELATIONSHIPS; MYELOGENOUS LEUKEMIA STEM; IN-VIVO ACTIVITY; ANTITUMOR AGENTS; ALPHA-METHYLENE; PROSTATE-CANCER; EXPRESSION PROFILES; MEDICINAL-PLANTS; TUMOR INHIBITORS;

D O I：

10.1016/j.drudis.2010.06.002

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Sesquiterpene lactones (SLs) are plant-derived compounds often used in traditional medicine against inflammation and cancer. This review focuses on the chemical and biological properties of SLs that lead to enhanced anticancer and anti-inflammatory effects. The chemical properties comprise alkylating center reactivity, lipophilicity, and molecular geometry and electronic features. SLs in clinical trials are artemisinin, thapsigargin and parthenolide and many of their synthetic derivatives. These drugs are selective toward tumor and cancer stem cells by targeting specific signaling pathways, which make them lead compounds in cancer clinical trials.

引用

页码：668 / 678

页数：11

共 70 条

[1] Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF-kB activation [J].

Aldieri, E ;

Atragene, D ;

Bergandi, L ;

Riganti, C ;

Costamagna, C ;

Bosia, A ;

Ghigo, D .

FEBS LETTERS, 2003, 552 (2-3) :141-144

[2] Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artemisinins [J].

Anfosso, L. ;

Efferth, T. ;

Albini, A. ;

Pfeffer, U. .

PHARMACOGENOMICS JOURNAL, 2006, 6 (04) :269-278

[3] Drug discovery from medicinal plants [J].

Balunas, MJ ;

Kinghorn, AD .

LIFE SCIENCES, 2005, 78 (05) :431-441

[4] Structure - Cytotoxicity relationships of some helenanolide-type sesquiterpene lactones [J].

Beekman, AC ;

Woerdenbag, HJ ;

vanUden, W ;

Pras, N ;

Konings, AWT ;

Wikstrom, HV ;

Schmidt, TJ .

JOURNAL OF NATURAL PRODUCTS, 1997, 60 (03) :252-257

[5]

Berger TG, 2005, ONCOL REP, V14, P1599

[6] Sesquiterpene lactone containing Mexican Indian medicinal plants and pure sesquiterpene lactones as potent inhibitors of transcription factor NF-kappa B [J].

Bork, PM ;

Schmitz, ML ;

Kuhnt, M ;

Escher, C ;

Heinrich, M .

FEBS LETTERS, 1997, 402 (01) :85-90

[7] Cytotoxic activity of some natural and synthetic sesquiterpene lactones [J].

Bruno, M ;

Rosselli, S ;

Maggio, A ;

Raccuglia, RA ;

Bastow, KF ;

Wu, CC ;

Lee, KH .

PLANTA MEDICA, 2005, 71 (12) :1176-1178

[8] Cytotoxic activity of some natural and synthetic guaianolides [J].

Bruno, M ;

Rosselli, S ;

Maggio, A ;

Raccuglia, RA ;

Bastow, KF ;

Lee, KH .

JOURNAL OF NATURAL PRODUCTS, 2005, 68 (07) :1042-1046

[9] Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1 [J].

Chen, HH ;

Zhou, HJ ;

Wu, GD ;

Lou, XE .

PHARMACOLOGY, 2004, 71 (01) :1-9

[10] A Trojan Horse in Drug Development: Targeting of Thapsigargins Towards Prostate Cancer Cells [J].

Christensen, S. Brogger ;

Skytte, Dorthe Mondrup ;

Denmeade, Samuel R. ;

Dionne, Craig ;

Moller, Jesper Vuust ;

Nissen, Poul ;

Isaacs, John T. .

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2009, 9 (03) :276-294

← 1 2 3 4 5 6 7 →